Highly Purified EPA-FFA Reduces Fecal Calprotectin in Ulcerative Colitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a more potent and active omega-3 polyunsaturated fatty acid (PUFA) with greater in vivo stability and purity to effectively reduce fecal calprotectin levels and relapses in subjects with ulcerative colitis.
Innovation Solution
The use of highly purified eicosapentaenoic acid (EPA) in the form of free fatty acids (EPA-FFA) with a purity of at least 90%, preferably 95%, and most preferably 99%, administered in therapeutic amounts to reduce fecal calprotectin levels below 150 μg/g and prevent clinical relapses in ulcerative colitis patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard fish oil supplements are used, then omega-3 PUFA intake is provided, but the purity and in vivo stability are insufficient to effectively reduce fecal calprotectin levels
Solution Approach 1:
The patent extracts and isolates eicosapentaenoic acid (EPA) from complex fish oil sources to create a highly purified free fatty acid formulation. This extraction process removes impurities and other fatty acids that reduce effectiveness, concentrating the active EPA component at ≥90% purity to reliably reduce fecal calprotectin levels in ulcerative colitis patients.
Solution Approach 2:
The patent changes the chemical form of EPA from esterified forms found in standard fish oil to free fatty acid form. This parameter change in molecular structure improves in vivo stability and bioavailability, enabling the supplement to effectively reduce fecal calprotectin levels where standard formulations fail.
2Reliability
If n-3 PUFAs are administered to UC patients, then anti-inflammatory effects are theoretically achieved, but clinical results are controversial and conflicting
Solution Approach 1:
The patent employs a simple, single-component EPA-FFA supplement that can be used independently without complex combination therapies. This disposable-style approach—using one well-defined active ingredient at a time—simplifies the treatment protocol while achieving reliable clinical results, avoiding the complexity of multiple conflicting interventions.
Solution Approach 2:
The patent changes the dosage form to highly purified free fatty acid EPA at ≥90% purity, which provides consistent and reliable anti-inflammatory effects in UC patients. This standardized parameter (purity and form) resolves the controversy by providing a uniform, well-defined treatment that produces reproducible clinical outcomes.
3Reliability
If EPA is used in non-free fatty acid form, then omega-3 supplementation is provided, but in vivo stability and potency are reduced
Solution Approach 1:
The patent changes the chemical form parameter of EPA from esterified or triglyceride forms to free fatty acid form. This parameter change dramatically improves in vivo stability and potency, allowing the EPA to maintain its anti-inflammatory activity in the gastrointestinal tract. The free fatty acid form is more resistant to degradation and provides more reliable therapeutic effects.
Data Source
AI summary
A method of administering an effective dose of highly purified eicosapentaenoic acid as free-fatty acid (EPA-FFA) to reduce fecal calprotectin levels and reduce the risk of clinical relapse in UC patients. The eicosapentaenoic acid, in the free fatty acid (EPA-FFA) form, has a purity of at least 95%, and more preferably at least 99%.